Industry Events at #ASBRS22

Moderator: Susan Boolbol, MD
Panelists: Brigid Killelea, MD, FACS, Michael Alvarado, MD, Anne Peled, MD, and Lucy De La Cruz, MD

Not all seeds and tracers are created equal… join us as we take a deep-dive in to the technologies currently available for seed localization and axillary staging, alongside a world-class panel of breast surgical oncologists, with years of collective experience across all available seed localization devices on the market. The great localization debates will tackle everything from seed reliability to MRI visibility, metal instruments, accuracy of measurement, clinical efficacy, and much more.

That’s followed by the world-first, in-person launch of the next generation Sentimag® system and new Magseed® markers - built by Endomag, designed by you. Taking on board feedback from thousands of physicians worldwide, see how the new system has built on the strengths that have made Sentimag® so widely adopted, plus added an abundance of new advanced features.

For more information, contact Kirsten Gonya, at kirsten.m.gonya@medtronic.com. For additional education opportunities, visit rtg.medtronicacademy.com/breast.

Program Objectives:

• Learn about the recently released data from the RxPONDER trial and how the Oncotype DX Breast Recurrence Score® test can help inform chemotherapy treatment decisions for node-positive breast cancer patients
• Explore how the Breast Recurrence Score® test and RSClin™ tool can help physicians personalize chemotherapy treatment decisions for node-negative breast cancer patients
• Explore ongoing studies on gene signatures that may help identify candidates for radiation therapy deceleration

Program Description:

Dr. Christy Russell (Vice President, US Medical Affairs) will lead a discussion exploring how the Breast Recurrence Score® test can help inform systemic therapy decisions for early node-negative and node-positive breast cancer patients. She will also explore ongoing studies on gene signatures that may help personalize radiotherapy decisions in early breast cancer.

For more information, please contact Thomas Mallick, tmallick@exactsciences.com, 650‑208‑3268.

For more information, contact Stacy Atkinson, MS, CM, at statkins@montefiore.org.

For more information, contact MedEd-BSH@hologic.com. For additional education opportunities, visit HologicED.com.

Description:

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to Targeted Axillary Dissection to excellent surgical outcomes. Discover the state-of-the art localization and lymphatic mapping techniques practiced by key opinion leaders from the Cleveland Clinic and University of Colorado. Learn about upcoming SCOUT product enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy.

Presenters:

Brian Czerniecki, MD, PhD; Colleen Murphy, MD, FACS; Stephanie Valente, DO, FACS

Program Objectives:

Upon completion of this CE activity, participants will be able to:

1. Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer
2. Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing
3. Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials
4. Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment

Description:

Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection.

This PeerView Live Clinical Consults event for in-person and virtual attendees will provide essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.

Note: This satellite symposium is supported by AstraZeneca and Merck & Co., Inc. through independent educational grants. This activity is provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. CME credits for this activity will be provided by Medical Learning Institute, Inc. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent symposium fee from Medical Learning Institute, Inc. was provided to the ASBrS in order to offer this satellite symposium during the 23rd Annual Meeting.)

Featured Guests:

• Moderator: Dr. Richard Fine, Margaret West Comprehensive Breast Center, Memphis, TN
• Dr. Amelia Tower, Texas Health Breast Specialists, Fort Worth, TX
• Dr. Maryam Elmi, The START Center for Cancer Care, San Antonio, TX

Join us for an educational session on the intraoperative use of Perimeter’s groundbreaking margin visualization technology powered by Optical Coherence Tomography (OCT), bringing clarity to margin status at the point of care.

This presentation will cover:

• Technology behind Perimeter’s S-Series OCT, delivering high-resolution specimen imaging for intraoperative margin visualization
• OCT correlations with pathology
• Workflow for bringing OCT into your OR
• Lumpectomy case reviews, including recognizing suspicious tissues
• Bringing AI* to the operating room and investigational study updates
• Panel discussion and Q&A

*Perimeter is currently conducting a randomized control trial to assess its B-Series OCT imaging platform combined with AI technology on the impact of positive margin rates during breast conservation surgery. Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States. CAUTION: Investigational Device. Limited by U.S. law to investigational use.

Perimeter’s S-Series OCT is cleared by the FDA and available for sale in the U.S.

For more information, contact Israel Madera at israel.madera@agendia.com or visit www.agendia.com.

Program Objective:

Go beyond wire-free localization into the advanced procedures of TAD and Delayed SLNB. Top experts from around the world review the latest data, the emerging procedures, and share their OR footage of their experiences. Get a glimpse of what’s on the horizon with the next generation Sentimag and dive into the ongoing research.

Agenda:

The Latest Magseed® TAD Data
Mr. Peter Barry, London’s Royal Marsden

Delayed SLNB: The Future of Axillary Staging
Kandace P. McGuire, MD - VCU
Melissa Fana, MD - Northwell Health

Magtrace Efficacy for SLNB Post-NAC
Dr. Stefan Paepke, MD - Technical University of Munich

SentiNOT 2.0 Trial and Recruitment Process
Betsy Bonefas, MD – Baylor College of Medicine

For more information, contact Kimmy Sullivan at kimmy.sullivan@stryker.com or visit www.SafeOR.com.

For more information, visit www.3m.com/medical.

For more information, visit www.astrazeneca.com/our-therapy-areas/oncology/breast-cancer.html.

Overview:

During this live satellite symposium, a multidisciplinary panel of experts in the management of early-stage HR+/HER2- breast cancer will engage in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics will include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents. This program will highlight current best practices and the integration of emerging data into daily practice to optimize outcomes for patients with early-stage HR+/HER2- breast cancer, using a lively tumor-board format with opportunity for audience questions and interaction.

For help or questions please contact: info@gotoper.com.

For more information and additional educational programs, visit www.viderasurgical.com/articles-news.